With specialty medicines driving growth, cash generation strengthening and the pipeline accelerating, GSK’s fair value looks ...
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate ...
The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).
The average one-year price target for GSK (OTCPK:GLAXF) has been revised to $23.15 / share. This is an increase of 11.52% from the prior estimate of $20.76 dated November 9, 2025. The price target is ...
GSK GSK stock has risen 18.6% in the past three months. The price recovery was backed by strong third-quarter results, wherein the British drugmaker beat estimates for both earnings and sales. The ...
Investor's Business Daily on MSN
GSK ADR earns IBD stock rating upgrade
GSK ADR saw an improvement in its IBD SmartSelect Composite Rating Friday, from 94 to 96.
GSK plc's ( LON:GSK ) strong earnings report was rewarded with a positive stock price move. We did some digging ...
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results